Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Rate ePoster

Head and Neck Surgery

(363) Overall Treatment Outcome and Recurrence Pattern of Olfactory Neuroblastoma

Monday, October 2, 2023
2:45 PM – 3:45 PM East Coast USA Time

    Presenting Author(s)

  • SC

    Sung-Woo Cho, MD

    MD
    Seoul National University Bundang Hospital
    Seongnam, Kyonggi-do, Republic of Korea

  • Chae-Seo Rhee, MD

    Professor
    Seoul National Universuty College of Medicine
    Seoul, Republic of Korea

    • Co-Author(s)

  • Dong-Young Kim, MD

    Professor
    Seoul National University Hospital
    Seoul, Seoul-t'ukpyolsi, KOR

  • JK

    Jeong-Whun Kim, MD

    Associate Professor
    Seoul National Universuty Bundang Hospital
    Seongnam, USA

    • Senior Author(s)

  • Tae-Bin Won, MD

    Professor
    Seoul National University Hospital
    Seoul, United States

Disclosure(s):
Sung-Woo Cho, MD: No relevant relationships to disclose.
Chae-Seo Rhee, MD: No relevant relationships to disclose.
Tae-Bin Won, MD: No relevant relationships to disclose.


Introduction: In this study we tried to evaluate a long-term treatment outcome of olfactory neuroblastoma (ONB).

Methods: A retrospective review of patients was performed for those who had definitive treatment for ONB from 1992 to 2021. Tumor stage, treatment modalities, and survivals using Kaplan Meier and Cox’s-proportional hazard model were analyzed.

Results: Ninety-four patients were analyzed. Mean age was 41.4±14.1 years and mean duration of follow up was 89.8±78.6 months. In total, 75.5% underwent surgical resection with or without adjuvant therapy and the other 24.5% underwent definitive radiotherapy. The 10-year cancer specific survival (CSS) was 79.2%. Univariate cox-regression analysis revealed that Kadish Stage D (HR=6.66, 95% CI: 2.34-18.96) compared to others, Hayms grade III/IV (HR=13.11, 95% CI:1.58-109.04) compared to others, and definitive RT only (HR 5.76, 95% CI:2.04-16.26) compared to surgical resection were associated with poor cancer specific survival. Overall relapse rate was 42.6%. The 5-year CSS after initial relapse was significantly different among recur site; 82.5% for local, 85.7% for regional, 41.7% for meningeal, and 0% for distant (p < 0.001). The 5-year CSS after initial relapse was also affected by the following salvage treatment modality; 79.1% for surgery, 50.0% for RT, and 0% chemotherapy (p < 0.001). Kadish D (0 < 0.001), Hyams high grade (III/IV) (p=0.042), and definitive RT only (p=0.001) was associated with lower distant free survival.

Conclusions: In ONB, definitive RT without surgical resection, higher tumor stage and grade are associated with poor distant control and affect overall survival. Despite high relapse rate, surgery or RT as a salvage therapy significantly improved overall survival.